Stimulant therapy in the management of ADHD: mixed amphetamine salts (extended release)

Bibliography

• BIEDERMAN J: Attention-deficit/hyperactivity disorder: a selective overview. Biol. Psychiatry (2005) 57:1215-1220.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, FARAONE SV: Attention-deficit hyperactivity disorder. Lancet (2005) 366:237-248.
   PubMed Web of Science ®Google Scholar
• FARAONE SV, SERGEANT J, GILLBERG C, BIEDERMAN J: The worldwide prevalence of ADHD: is it an American condition? World Psychiatry (2003) 2:104-113.
   PubMedGoogle Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR 4th Edition, Text revision. American Psychiatric Association, Washington, DC. (2000).
   Google Scholar
• ST SAUVER JL, BARBARESI WJ, KATUSIC SK, COLLIGAN RC, WEAVER AL, JACOBSEN SJ: Early life risk factors for attention-deficit/hyperactivity disorder: a population-based cohort study. Mayo Clin. Proc. (2004) 79:1124-1131.
   PubMed Web of Science ®Google Scholar
• BRAUN JM, KAHN RS, FROEHLICH T, AUINGER P, LANPHEAR BP: Exposures to environmental toxicants and attention deficit hyperactivity disorder in US children. Environ. Health Perspect. (2006) 114:1904-1909.
   PubMed Web of Science ®Google Scholar
• FARAONE SV, BIEDERMAN J, SPENCER TJ, ALEARDI M: Comparing the efficacy of medications for ADHD using meta-analysis. Med. Gen. Med (2006) 8:4.
   PubMedGoogle Scholar
• FARAONE SV, WILENS T: Does stimulant treatment lead to substance use disorders? J. Clin. Psychiatry (2003) 64(Suppl. 11):9-13.
   PubMed Web of Science ®Google Scholar
• WILENS TE: Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr. Clin. North Am. (2004) 27:283-301.
   PubMed Web of Science ®Google Scholar
• WILENS TE, FARAONE SV, BIEDERMAN J, GUNAWARDENE S: Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics (2003) 111:179-185.
   PubMed Web of Science ®Google Scholar
• FARAONE SV, WILENS TE: Effect of stimulant medications on later substance use and the potential for misuse, abuse, and diversion. J. Clin. Psychiatry (2007) (In Press).
   Google Scholar
• WILSON JJ: ADHD and substance use disorders: developmental aspects and the impact of stimulant treatment. Am. J. Addict. (2007) 16(Suppl. 1):5-11.
   PubMed Web of Science ®Google Scholar
• TULLOCH SJ, ZHANG Y, MCLEAN A, WOLF KN: SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy (2002) 22:1405-1415.
   PubMed Web of Science ®Google Scholar
• WILENS TE, SPENCER TJ: The stimulants revisited. Child Adolesc. Psychiatr. Clin. North Am. (2000) 9:573-603.
   PubMed Web of Science ®Google Scholar
• CALDWELL J, SEVER PS: The biochemical pharmacology of abused drugs. I. Amphetamines, cocaine, and LSD. Clin. Pharmacol. Ther. (1974) 16:625-638.
   PubMed Web of Science ®Google Scholar
• ARNOLD LE, HUESTIS RD, SMELTZER DJ, SCHEIB J, WEMMER D, COLNER G: Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating. Arch. Gen. Psychiatry (1976) 33:292-301.
   PubMed Web of Science ®Google Scholar
• ARNOLD LE, KIRILCUK V, CORSON SA, CORSON EO: Levoamphetamine and dextroamphetamine: differential effect on aggression and hyperkinesis in children and dogs. Am. J. Psychiatry (1973) 130:165-170.
   PubMed Web of Science ®Google Scholar
• ARNOLD LE, WENDER PH, MCCLOSKEY K, SNYDER SH: Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms. Arch. Gen. Psychiatry (1972) 27:816-822.
   PubMed Web of Science ®Google Scholar
• ADDERALL XR (Package insert). WAYNE PA: Shire US, Inc. (2007).
   Google Scholar
• MCGOUGH JJ, BIEDERMAN J, GREENHILL LL et al.: Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42:684-691.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, LOPEZ FA, BOELLNER SW, CHANDLER MC: A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics (2002) 110:258-266.
   PubMed Web of Science ®Google Scholar
• MCCRACKEN JT, BIEDERMAN J, GREENHILL LL et al.: Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42:673-683.
   PubMed Web of Science ®Google Scholar
• SPENCER TJ, WILENS TE, BIEDERMAN J, WEISLER RH, READ SC, PRATT R: Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. (2006) 28:266-279.
   PubMed Web of Science ®Google Scholar
• GRCEVICH S, READ SC, SEA D, MAYS DA, TULLOCH SJ: Safety and efficacy of MAS XR in adolescents with ADHD. American Academy of Child and Adolescent Psychiatry 51st Annual Meeting. Washington, DC (19 – 24 October 2004).
   Google Scholar
• SPENCER TJ, BIEDERMAN J, WILENS TE: Efficacy and tolerability of long-term, open-label, mixed amphetamine salts extended release in adolescents with ADHD. CNS Spectr. (2005) 10:14-21.
   Web of Science ®Google Scholar
• MCGOUGH JJ, BIEDERMAN J, WIGAL SB et al.: Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry (2005) 44:530-538.
   PubMed Web of Science ®Google Scholar
• WIGAL SB, MCGOUGH JJ, MCCRACKEN JT et al.: A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J. Atten. Disord. (2005) 9:275-289.
   PubMedGoogle Scholar
• FARAONE SV, WIGAL SB, HODGKINS P: Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with ADHD. J. Atten. Disord. (2007) 11:74-82.
   PubMedGoogle Scholar
• WEISLER RH, BIEDERMAN J, SPENCER TJ et al.: Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. (2006) 11:625-639.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, SPENCER TJ, WILENS TE, WEISLER RH, READ SC, TULLOCH SJ: Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. (2005) 10:16-25.
   PubMed Web of Science ®Google Scholar
• WEISLER RH: Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD. Expert Opin. Pharmacother. (2005) 6:1003-1018.
   PubMed Web of Science ®Google Scholar
• FARAONE SV, BIEDERMAN J, MONUTEAUX M, SPENCER T: Long-term effects of extended-release mixed amphetamine salts treatment of attention-deficit/hyperactivity disorder on growth. J. Child Adolesc. Psychopharmacol. (2005) 15:191-202.
   PubMed Web of Science ®Google Scholar
• SUND AM, ZEINER P: Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children? Nord. J. Psychiatry (2002) 56:53-57.
   PubMed Web of Science ®Google Scholar
• SCHERTZ M, ADESMAN AR, ALFIERI NE, BIENKOWSKI RS: Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics (1996) 98:763-769.
   PubMed Web of Science ®Google Scholar
• KAFFMAN M, SHER A, BAR-SINAI N: MBD children-variability in developmental patterns or growth inhibitory effect of stimulants? Isr. Ann. Psychiatr. Relat. Discip. (1979) 17:58-66.
   PubMedGoogle Scholar
• GROSS MD: Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. Pediatrics (1976) 58:423-431.
   PubMed Web of Science ®Google Scholar
• WEISLER RH, BIEDERMAN J, SPENCER TJ, WILENS TE: Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. (2005) 10(Suppl. 20):35-43.
   PubMed Web of Science ®Google Scholar
• FINDLING RL, BIEDERMAN J, WILENS TE et al.: Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J. Pediatr. (2005) 147:348-354.
   PubMed Web of Science ®Google Scholar
• WILENS TE, ZUSMAN RM, HAMMERNESS PG et al.: An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. J. Clin. Psychiatry (2006) 67:696-702.
   PubMed Web of Science ®Google Scholar
• STEINHOFF KW: Attention-deficit/hyperactivity disorder: medication treatment-dosing and duration of action. Am. J. Manag. Care (2004) 10:S99-S106.
   Google Scholar
• WIGAL SB, BRAMS M, PENNICK M et al.: SPD465, a novel long-acting mixed amphetamine salts extended-release formulation. American Academy of Child and Adolescent Psychiatry 53rd Annual Meeting. San Diego, CA (24 – 29 October 2006).
   Google Scholar
• WIGAL T, CHILDRESS A, GOLARZ H, LI Y, YOUCHA SH: Clinical evaluation of SPD465, a novel ADHD compound. American Academy of Child and Adolescent Psychiatry 53rd Annual Meeting. San Diego, CA (24 – 29 October 2006).
   Google Scholar
• LANDGRAF JM, SPENCER TJ, YOUCHA SH, ANDERSON CS, SILVERBERG A: Triple-based amphetamine salts (SPD465) improves quality of life in adults with ADHD. 160th Annual Meeting of the American Psychiatric Association. San Diego, CA (19 – 24 May 2007).
   Google Scholar
• YOUCHA SH, SHOJAEI AH, ERMER JC: Pharmacokinetic evaluation of SPD465, a novel long-acting mixed amphetamine salts extended-release formulation. 19th US Psychiatric & Mental Health Congress. New Orleans, LA (15 – 19 November 2006).
   Google Scholar
• WIGAL T, KOLLINS S, GOLARZ H, SILVERBERG A, YOUCHA SH: SPD465 duration of effect: a prospective, double-blind, crossover study. American Academy of Child and Adolescent Psychiatry 53rd Annual Meeting. San Diego, CA (24 – 29 October 2006).
   Google Scholar
• WILENS TE, GIGNAC M, SWEZEY A, MONUTEAUX MC, BIEDERMAN J: Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J. Am. Acad. Child Adolesc. Psychiatry (2006) 45:408-414.
   PubMed Web of Science ®Google Scholar
• VOLKOW ND, SWANSON JM: Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am. J. Psychiatry (2003) 160:1909-1918.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, KRISHNAN S, ZHANG Y, MCGOUGH JJ, FINDLING RL: Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a Phase III, multicenter, randomized, double-blind, parallel-group study. Clin. Ther. (2007) 29:450-463.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, BOELLNER SW, CHILDRESS A, LOPEZ F, KRISHNAN S, HODGKINS P: Improvements in symptoms of attention-deficit/hyperactivity disorder in school-aged children with lisdexamfetamine (NRP104) and mixed amphetamine salts, extended-release versus placebo. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (25 – 28 May 2006).
   Google Scholar
• ERMER JC, SHOJAEI A, BIEDERMAN J, KRISHNAN S: Improved interpatient pharmacokinetic variability of lisdexamfetamine dimesylate compared with mixed amphetamine salts extended release in children aged 6 to 12 years with attention-deficit/hyperactivity disorder. American Psychiatric Association 160th Annual Meeting. San Diego, CA (19 – 24 May 2007).
   Google Scholar
• BIEDERMAN J, BOELLNER SW, CHILDRESS A, LOPEZ FA, KRISHNAN S, ZHANG Y: Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol. Psychiatry (2007) (In Press).
   Google Scholar
• FINDLING RL, CHILDRESS AC, KRISHNAN S, MCGOUGH J: Long-term efficacy and safety of lisdexamfetamine in school-age children with attention-deficit/hyperactivity disorder. American Psychiatric Association 160th Annual Meeting. San Diego, CA (19 – 24 May 2007).
   Google Scholar
• FARAONE SV, BIEDERMAN J, ROE C: Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J. Clin. Psychopharmacol. (2002) 22:468-473.
   PubMed Web of Science ®Google Scholar
• ARNOLD LE: Methylphenidate vs. amphetamine: comparative review. J. Atten. Disord. (2000) 3:200-211.
   Google Scholar
• STEIN MA, WALDMAN ID, SARAMPOTE CS et al.: Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology (2005) 30:1374-1382.
   PubMed Web of Science ®Google Scholar